Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813428 | 0.78 | TP53 (0.36) | MMP1MMP9MMP12TP53LMNA | |
| SCHEMBL27405676 | 0.74 | SMN1; SMN2 (0.38) | MMP1MMP9MMP12TP53LMNA | |
| SCHEMBL10934944 | 0.74 | MMP1 (0.35) | MMP1MMP9MMP12TP53LMNA | |
| SCHEMBL28259277 | 0.74 | SRC (0.45) | MMP1MMP9MMP12ALDH1A1 | |
| SCHEMBL9807542 | 0.74 | MMP1 (0.39) | MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL27531645 | 0.72 | SRC (0.43) | MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL28645830 | 0.72 | SRC (0.43) | MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL5806298 | 0.71 | SRC (0.42) | MMP1MMP9MMP12ALDH1A1 | |
| Water SCHEMBL5807227 | 0.71 | MMP1 (0.33) | MMP1MMP9MMP12ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL5804521 | 0.71 | SRC (0.42) | MMP1MMP9MMP12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-6376539-B1 | ANTIISCHEMIC AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1047686-A1 | SUBSTITUTED BICYCLIC LACTONES | Bayer Aktiengesellschaft (DE) | 2000-11-02 | — | — | EP | disclosed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999036418-A1 | SUBSTITUTED BICYCLIC LACTONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-22 | — | — | WO | disclosed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |